TriSalus Life Sciences Inc.
Last updated September 27, 2026
Organization details
- Legal name
- TriSalus Life Sciences Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- TLSI
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001826667
Board of directors
-
Anil K. Singhal · DirectorSince 2023
-
Arjun Jj Desai · DirectorSince 2023
-
David J. Matlin · DirectorSince 2023
-
Eschenbach Andrew C. Von · DirectorSince 2023
-
Gary B. Gordon · DirectorSince 2025
-
George Kelly Martin · DirectorSince 2023
-
Kerry R. Hicks · DirectorSince 2023
-
Liselotte Hyveled · DirectorSince 2024
-
Mary T. Szela · Director · CEO and PresidentSince 2023
-
Mats Wahlstrom · DirectorSince 2023
-
Michael P. Stansky · DirectorSince 2026
-
Sean Murphy · Director · Chief Manuf, Strategy&Bus Dev.Since 2023
-
William Valle · DirectorSince 2025
Chief executives
Mary T. Szela
· CEO AND PRESIDENT
Dates unknown
Board connections
6 of this board's directors also sit on 9 other boards.
- via Arjun Jj Desai and David J. Matlin
- via Mary T. Szela
- via Mary T. Szela
- via Eschenbach Andrew C. Von
- via Eschenbach Andrew C. Von
- via Mats Wahlstrom
- via Mary T. Szela
- via Arjun Jj Desai
- via Anil K. Singhal
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $3,606,918
- 12 purchases by 6 insiders
- Sold, last 12 months
- $135,808
- 15 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 1, 2026 | Patience David Officer (Chief Financial Officer) | Shares withheld for tax | −14,650 | $4.46 | $65,339 |
| Jun 30, 2026 | Marshak Richard Officer (Chief Commercial Officer) | Grant or award | +561 | $3.87 | $2,171 |
| Jun 30, 2026 | Mary T. Szela Director, Officer (CEO and President) | Grant or award | +3,990 | $3.87 | $15,441 |
| Jun 29, 2026 | Marshall Richard Henry Officer (Chief Medical Officer) | Grant or award | +60,000 | — | — |
| May 15, 2026 | Marshak Richard Officer (Chief Commercial Officer) | Open-market sale | −543 | $2.67 | $1,450 |
| May 15, 2026 | Mats Wahlstrom Director | Open-market purchase | +60,000 | $2.53 | $151,800 |
| May 15, 2026 | Michael P. Stansky Director | Open-market purchase | +410,000 | $2.50 | $1,025,000 |
| May 15, 2026 | Mary T. Szela Director, Officer (CEO and President) | Open-market purchase | +39,682 | $2.59 | $102,776 |
| May 15, 2026 | Patience David Officer (Chief Financial Officer) | Open-market purchase | +7,100 | $2.43 | $17,253 |
| May 15, 2026 | Gary B. Gordon Director | Open-market purchase | +10,000 | $2.46 | $24,600 |
| May 15, 2026 | Michael P. Stansky Director | Open-market purchase | +200,000 | $2.50 | $500,000 |
| May 14, 2026 | Kerry R. Hicks Director | Grant or award | +28,201 | — | — |
| May 14, 2026 | Mats Wahlstrom Director | Grant or award | +37,602 | — | — |
| May 14, 2026 | Gary B. Gordon Director | Grant or award | +28,201 | — | — |
| May 14, 2026 | David J. Matlin Director | Grant or award | +28,201 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.